pretickt

CRSP price target

CRISPR Therapeutics AG · end-of-day data as of Nov 13, 2026

CRISPR Therapeutics
CRSP · $4.1B
$42.24-0.9%
Nov 13, 2026 · close
$50$60SepOctNov9:3016:003 months -20.3%Nov 13 · close
▲ 4
  • PT$72.45 +71.5%
  • ConsensusBuy · 23
  • Bollingerbelow lower
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • RSI32
  • Support-7.6%
  • Resistance+0.3%
  • Off 52w high-33.4%
  • Volume1.2x
  • News0.00
  • Trendsideways
  • 52w range$42–$63
  • ATR+6.3%
  • Off ATH-80.8%
▼ 4
  • FCF yield-9.3%
  • Insiders-$4.88M
  • MAs0 of 4
  • MACD-0.81

Updates with the 15-min delayed price. Not a forecast or investment advice.

The average price target of the 11 analyst firms that published one in the last 12 months is $72.45 for CRISPR Therapeutics CRSP, 71.5% above the last close of $42.24 on Nov 13, 2026. Targets range from $52.00 to $110.00, with a median of $76.00. Rating consensus: Buy.

Summary

  • Price target at+71.5%
  • ConsensusBuy

Analyst price targets

11 firms with a target in the last 12 months · last close $42.24 · as of Nov 13, 2026

— actual price● bullish target● bearish target┄ last close, high, average and low targethover a dot to see the analysts behind it ·wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets
⇔⇕$110HIGH$72.45AVERAGE$52.00LOW$42.24TODAYNov 25Apr 26Sep 26Feb 27Jul 27Dec 27+75%+83%-22%+80%+37%+89%+30%+23%+78%+160%
31

Strong buy 4Buy 9Hold 10Sell 0Strong sell 0

23 analysts in November 2026: 13 rate it a buy or strong buy (57%) and 10 a hold. A year earlier, 62% rated it a buy or strong buy.